Quality of Life in CKD Patients Treated With Erythropoiesis-Stimulating Agents

American Journal of Kidney Diseases

Volumn 55, Issue 3, 2010, Pages 423-425

  Parfrey, Patrick S ^a   Wish, Tyler ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CHRONIC KIDNEY DISEASE; EDITORIAL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; QUALITY OF LIFE; STROKE;

ANEMIA; CHRONIC DISEASE; HEMATINICS; HUMANS; KIDNEY DISEASES; QUALITY OF LIFE;

EID: 77049094944     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.014     Document Type: Editorial

References (16)

1. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 200 (1990) 573-578
2. Delano B.G. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14 (1989) 14-18
3. Evans R.W., Rader B., and Manninen D.L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263 (1990) 825-830
4. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
5. Parfrey P., Foley R., Wittreich B., Sullivan D., Zagari M., Frei D., and Canadian European Study Group. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
6. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
7. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 35 (2006) 2071-2084
8. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009) 2019-2032
9. Gandra S.R., Finkelstein F.O., Bennett A.V., Lewis E.F., Bragg T., and Martin M.L. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 55 3 (2010) 519-534
10. Johansen K.L., Finkelstein F.O., Revicki D.A., Gitlin M., Evans C., and Mayne T.J. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55 3 (2010) 535-548
11. US Renal Data System. Morbidity and mortality. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States (2008), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD chapt 6
12. Finkelstein F.O., Wuerth D., and Finkelstein S.H. Health related quality of life and the CKD patient: challenges for the nephrology community. Kidney Int 76 (2009) 946-952
13. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18 (1991) 49-50
14. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 548-554
15. Foley R.N., Curtis B.M., and Parfrey P.S. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 4 (2009) 726-733
16. Foley R.N., Curtis B.M., and Parfrey P.S. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 3 (2008) 1669-1675